Syndax Pharmaceuticals, Inc.
Financials
Valuation Metrics
Syndax Pharmaceuticals, Inc.'s Market Cap is $1.56B. At end of 2025 it was $1.82B. Ranked #2197 of 3,121 in US market (top 70%), #868 of 1,463 on NASDAQ (top 59%), #161 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 61%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.56B | US#2,197/3,121 Sec#161/266 |
| Revenue | $252M | US#2,521/3,121 Sec#102/266 |
| Net Income | $-221M | US—/3,121 Sec—/266 |
| Total Assets | $704M | US#2,626/3,121 Sec#131/266 |
| Net Assets | $15M | US#2,904/3,121 Sec#236/266 |
| Employees | 298 | US#2,422/3,121 Sec#111/266 |
| Value | ||
| P/B | 103.40x | US#2,909/3,121 Sec#236/266 |
| P/S | 6.20x | US#2,457/3,121 Sec#91/266 |
| FCF Yield | -14.15% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROA | -31.37% | US#2,893/3,121 Sec#158/266 |
| Op. Margin | -77.05% | US#2,712/3,121 Sec#115/266 |
| Revenue Growth | 222.34% | US#48/3,121 Sec#20/266 |
| Financial Health | ||
| Debt Ratio | 4560.26% | US#2,908/3,121 Sec#241/266 |
| Total Debt | $589M | US#1,795/3,121 Sec#60/266 |
| FCF | $-221M | US#2,795/3,121 Sec#214/266 |
| Cash | $336M | US#1,342/3,121 Sec#75/266 |
| Current Ratio | 6.77x | US#369/3,121 Sec#115/266 |
| Performance | ||
| 1Y Return | 14.05% | US#1,163/3,121 Sec#155/266 |
| 1M Return | -15.17% | US#2,553/3,121 Sec#196/266 |
| From 52W High | -31.14% | US#2,110/3,121 Sec#165/266 |
| 1Y MDD | -32.56% | US#1,598/3,121 Sec#105/266 |
| Trading | ||
| Volume | 5,069,674 shares | US#703/3,121 Sec#70/266 |
| Trading Value | $89M | US#1,342/3,121 Sec#104/266 |
| Per Share | ||
| EPS | $-2.49 | US—/3,121 Sec—/266 |
| BPS | $0.17 | US#2,795/3,121 Sec#230/266 |
Company Info
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.